These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 29545238)

  • 1. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial SCUBE2 Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis.
    Lin YC; Chao TY; Yeh CT; Roffler SR; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):144-155. PubMed ID: 27834687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dioscin inhibits colon tumor growth and tumor angiogenesis through regulating VEGFR2 and AKT/MAPK signaling pathways.
    Tong Q; Qing Y; Wu Y; Hu X; Jiang L; Wu X
    Toxicol Appl Pharmacol; 2014 Dec; 281(2):166-73. PubMed ID: 25111127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
    Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
    Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
    Ma Q; Chen W; Chen W
    Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.
    Al-Hilal TA; Chung SW; Choi JU; Alam F; Park J; Kim SW; Kim SY; Ahsan F; Kim IS; Byun Y
    J Clin Invest; 2016 Apr; 126(4):1251-66. PubMed ID: 26950422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
    Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
    Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
    Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
    Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
    Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
    Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.
    Pal HC; Sharma S; Strickland LR; Agarwal J; Athar M; Elmets CA; Afaq F
    PLoS One; 2013; 8(10):e77270. PubMed ID: 24124611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
    Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
    Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
    Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
    Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.